InvestmentPitch Media Video Discusses Pascal Biosciences and its Award of a National Cancer Institute Grant for its Acute Lymphoblastic Leukemia Program – Video Available on Investmentpitch.com
03 November 2021 - 5:22PM
Pascal Biosciences (TSXV:PAS) (OTCPink:PSCBF) (FSE:6PB), a
biotechnology company targeting innovative therapies for serious
diseases, including COVID-19, has been awarded a grant from the
National Cancer Institute of the US National Institutes of Health.
This two-year grant of US$343,750 will fund development of Pascal's
antibody drug for Acute Lymphoblastic Leukemia or “ALL”.
For more information, please view the
InvestmentPitch Media “video” which provides additional information
about this news and the company, along with some comments
from Dr. Patrick Gray, CEO of Pascal Biosciences. If this
link is not enabled, please visit www.InvestmentPitch.com and enter
“Pascal” in the search box.
More than 6,000 patients are diagnosed with this
type of leukemia in North America each year, with about half being
children, making this the most common childhood leukemia.
Pascal's drug will be eligible for orphan drug
designation, which can enable financial incentives and a seven year
marketing exclusivity. Although the number of patients with ALL is
relatively small, the market potential for Pascal's drug could be
significant. Other cancer products for orphan diseases have proven
to be financially successful, selling over $1 billion each
year.
The company has filed for patent protection for
its ALL treatment.
Pascal recently appointed Mark van der Horst as
President. As the president of Gale Capital Corporation since 1993,
Mark has extensive capital markets experience and has been CEO of
two publicly listed companies on the Canadian Securities
Exchange.
The shares are currently trading at $0.12 on the
TSX Venture Exchange and recently began trading on the OTC markets
under the symbol PSCBF.
For more information, please visit the company’s
website at www.PascalBiosciences.com, contact Dr. Patrick W. Gray,
CEO, at 206-221-3443, or by email at invest@PascalBiosciences.com.
For investor relations, contact Mark van der Horst, President, at
604-760-7604 or by email at mark@GaleCapital.com.
About InvestmentPitch Media
Investmentpitch Media leverages the power of
video, which together with its extensive distribution, positions a
company’s story ahead of the 1,000's of companies seeking awareness
and funding from the financial community. The company specializes
in producing short videos based on significant news releases,
research reports and other content of interest to investors.
CONTACT: InvestmentPitch Media Barry Morgan, CFO
bmorgan@investmentpitch.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/535f4faf-140d-46a4-b8a1-072d8f8f28d7
Pascal Biosciences (TSXV:PAS)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Pascal Biosciences (TSXV:PAS)
Historical Stock Chart
Von Dez 2023 bis Dez 2024